HDR Gateway logo
HDR Gateway logo

Bookmarks

Cardiovascular Disease (Cvd)-covid-uk / Covid-impact

Cardiovascular disease (CVD)-COVID-UK / COVID-IMPACT

Description

CVD-COVID-UK, co-ordinated by the British Heart Foundation (BHF) Data Science Centre, is one of the NIHR-BHF Cardiovascular Partnership’s National Flagship Projects.

It aims to understand the relationship between COVID-19 and cardiovascular diseases such as heart attack, heart failure, stroke, and blood clots in the lungs through analyses of de-identified, pseudonymised, linked, nationally collated health datasets across the four nations of the UK.

The consortium has over 380 members across more than 50 institutions including data custodians, data scientists with methodological and analytical expertise and clinicians, all of whom have signed up to an agreed set of principles with an inclusive, open and transparent ethos.

Approved researchers access data within secure trusted research environments (TREs) provided by NHS England in England, the National Data Safe Haven in Scotland, the SAIL Databank in Wales and the Honest Broker Service in Northern Ireland.

Linkable datasets include those from primary and secondary care, COVID lab tests and vaccinations, deaths, critical care, prescribing/dispensing, cardiovascular and stroke audits, maternity services and mental health.

Building on the success of CVD-COVID-UK, the BHF Data Science Centre has now gained ethical and regulatory approval to broaden the scope of the programme to all COVID-related research (in NHS England’s TRE for England only). This is known as COVID-IMPACT and it helps to support research projects from the wider community.

More detail about CVD-COVID-UK / COVID-IMPACT, including a dashboard of datasets currently available in each nation’s TRE, can be found at: https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/

Datasets & BioSamples (63)

Secondary Uses Services Payment By Results
Dataset population size: Unknown
Health and disease
Covid-19 Second Generation Surveillance System
Dataset population size: Unknown
Health and disease
GPES Data for Pandemic Planning and Research (COVID-19)
Dataset population size: 56,441,600
Health and disease
COVID-19 Vaccination Adverse Reaction
Dataset population size: 2,600
Health and disease
Hospital Episode Statistics Critical Care
Dataset population size: Unknown
Health and disease
Hospital Episode Statistics Admitted Patient Care
Dataset population size: Unknown
Health and disease

Publications (28)

Testing for coronavirus (SARS-CoV-2) infection in populations with low infection prevalence: the largely ignored problem of false positives and the value of repeat testing
Sudlow C, Diggle P, Warlow O, Seymour D, Gordon B, Walker R, Warlow C.
2020
Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort.
Handy A, Banerjee A, Wood AM, Dale C, Sudlow CLM, Tomlinson C, Bean D, Thygesen JH, Mizani MA, Katsoulis M, Takhar R, Hollings S, Denaxas S, Walker V, Dobson R, Sofat R, CVD-COVID-UK Consortium.
2022
Association of COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-Wide Cohort Study of 48 Million Adults in England and Wales.
Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, Denholm R, Akbari A, Abbasizanjani H, Torabi F, Omigie E, Hollings S, North TL, Toms R, Jiang X, Angelantonio ED, Denaxas S, Thygesen JH, Tomlinson C, Bray B, Smith CJ, Barber M, Khunti K, Davey Smith G, Chaturvedi N, Sudlow C, Whiteley WN, Wood AM, Sterne JAC, CVD-COVID-UK/COVID-IMPACT Consortium and the Longitudinal Health and Wellbeing COVID-19 National Core Study.
2022
COVID-19 trajectories among 57 million adults in England: a cohort study using electronic health records.
Thygesen JH, Tomlinson C, Hollings S, Mizani MA, Handy A, Akbari A, Banerjee A, Cooper J, Lai AG, Li K, Mateen BA, Sattar N, Sofat R, Torralbo A, Wu H, Wood A, Sterne JAC, Pagel C, Whiteley WN, Sudlow C, Hemingway H, Denaxas S, Longitudinal Health and Wellbeing COVID-19 National Core Study and the CVD-COVID-UK/COVID-IMPACT Consortium.
2022
Risk of myocarditis and pericarditis following BNT162b2 and ChAdOx1 COVID-19 vaccinations
Ip S, Torabi F, Denaxas S, Akbari A, Abbasizanjani H, Knight R, Cooper J, Denholm R, Keene S, Bolton T, Hollings S, Omigie E, North T, Suseeladevi AK, Angelantonio ED, Khunti K, Sterne JAC, Sudlow C, Whiteley W, Wood A, Walker V.
2022
Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study.
Mizani MA, Dashtban A, Pasea L, Lai AG, Thygesen J, Tomlinson C, Handy A, Mamza JB, Morris T, Khalid S, Zaccardi F, Macleod MJ, Torabi F, Canoy D, Akbari A, Berry C, Bolton T, Nolan J, Khunti K, Denaxas S, Hemingway H, Sudlow C, Banerjee A, CVD-COVID-UK Consortium.
2023